Subgroup analysis suggests survival benefit in patients with advanced liver cancer treated with resminostat
4SC AG / Key word(s): Study results
Disclosure of an inside information according to Article 17 MAR,
transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
4SC AG: Subgroup analysis suggests survival benefit in patients with
advanced liver cancer treated with resminostat
Planegg-Martinsried, Germany, 5 October 2016 – 4SC AG (4SC, FSE Prime
Standard: VSC) and its development partner Yakult Honsha Co., Ltd. (Yakult
Honsha) retrospectively analyzed the data of the randomized, multicenter
Phase II study, conducted by Yakult Honsha in Japan and South Korea. The
study investigated the effect of 4SC’s epigenetic cancer drug resminostat
in combination with the standard of care drug sorafenib compared with
sorafenib monotherapy as a potential novel first-line treatment for
patients with advanced liver cancer (hepatocellular carcinoma, HCC).
Treatment with resminostat in combination with sorafenib demonstrated a
substantial overall survival (OS) benefit compared with sorafenib
monotherapy in a large subgroup comprised of 84 patients (50 % of all
patients in the study) with a greater than median platelet count at study
entry. As overall survival (OS) is the most relevant clinical endpoint in
advanced HCC, the findings of the subgroup analysis provide important
knowledge for the future clinical development of resminostat in combination
with sorafenib in this indication. Based on these results, 4SC and Yakult
are currently discussing their plans for continued clinical development of
The results of the study will be published by Yakult Honsha and the
investigators at an upcoming scientific conference.
Information and Explanation of the Issuer to this News:
4SC (www.4sc.com) is a biotech company dedicated to the research and
development of small-molecule drugs focused on epigenetic mechanisms of
action for the treatment of cancers with high unmet medical needs. These
drugs are intended to provide innovative treatment options for cancer
patients that are more tolerable and efficacious than existing therapies,
provide a better quality of life and offer increased life expectancy. The
Company’s pipeline comprises promising products that are in various stages
of clinical development. 4SC’s aim is to generate future growth and enhance
its enterprise value by entering into partnerships with pharmaceutical and
biotech companies. Founded in 1997, 4SC had 50 employees as of 30 June
2016. 4SC has been listed on the Prime Standard of the Frankfurt Stock
Exchange since December 2005.
Information set forth in this press release contains forward-looking
statements, which involve a number of risks and uncertainties. The forward-
looking statements contained herein represent the judgement of 4SC as of
the date of this press release. Such forward-looking statements are neither
promises nor guarantees, but are subject to a variety of risks and
uncertainties, many of which are beyond 4SC’s control, and which could
cause actual results to differ materially from those contemplated in these
forward-looking statements. 4SC expressly disclaims any obligation or
undertaking to release any updates or revisions to any such statements to
reflect any change in its expectations or any change in events, conditions
or circumstances on which any such statement is based.
4SC Corporate Communications & Investor Relations
The Ruth Group
05.10.2016 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de